The emerging use of the 20-μg oral contraceptive

被引:17
作者
Poindexter, A [1 ]
机构
[1] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA
关键词
low-dose oral contraceptive; ethinyl estradiol; efficacy; safety; cycle control; noncontraceptive health benefits; levonorgestrel; desogestrel; gestodene; norethindrone acetate;
D O I
10.1016/S0015-0282(00)01747-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To highlight studies that investigated the efficacy, safety, and tolerability of low-dose oral contraceptives (OCs) containing 20 mug of ethinyl estradiol (EE) and to discuss the use of these low-dose contraceptives in women from adolescence to menopause and the noncontraceptive health benefits likely to be afforded by low-dose contraceptives. Design: Relevant literature was identified by searching MEDLINE and EMBASE. Other sources were located by consulting the bibliographies of the material collected from Medline and EMBASE. Sources for additional information included documents from the United States Food and Drug Administration and the Physicians' Desk Reference (54th ed.). Conclusion(s): The current lowest available dose of EE used for OCs in the United States is 20 mug. Formulations with 20 mug of EE are efficacious and have a low incidence of estrogen-related side effects. Since this lowest effective EE dose inhibits ovarian activity, 20 mug of EE should also provide the noncontraceptive health benefits of OCs. Both contraceptive and noncontraceptive benefits of OCs are available to most women from adolescence to menopause without complications. (C) 2001 by American Society for Reproductive Medicine.
引用
收藏
页码:457 / 465
页数:9
相关论文
共 100 条
[1]  
ABMA JC, 1997, FERTILITY FAMILY PLA, V23
[2]  
Akerlund M, 1997, ACTA OBSTET GYN SCAN, V76, P63
[3]  
Akin M, 1998, AM J OBSTET GYNECOL, V179, pS2
[4]  
American College of Obstetricians and Gynecologists, 1992, J ADOLESCENT HEALTH, V13, P333
[5]  
[Anonymous], 1987, NEW ENGL J MED, V316, P650
[6]  
[Anonymous], 1988, Int J Epidemiol, V17, P263
[7]   A new low-dose monophasic combination oral contraceptive (Alesse(TM)) with levonorgestrel 100 mu g and ethinyl estradiol 20 mu g [J].
Archer, DF ;
Maheux, R ;
DelConte, A ;
OBrien, FB ;
Adams, D ;
Appel, T ;
Brown, D ;
Carr, B ;
Chenault, B ;
Connell, E ;
Davila, G ;
Donovan, S ;
Faguant, R ;
Glick, H ;
Grimes, D ;
Hanson, M ;
Harris, JW ;
Hume, J ;
Kasparian, S ;
Katz, D ;
Lifson, MS ;
Mercer, L ;
Merritt, D ;
Moore, D ;
Schade, G ;
Spellacy, W ;
Stephenson, CD ;
Stewart, SK ;
Thorp, JM ;
Varner, E ;
Wallach, E ;
Blanchet, P ;
Boroditsky, R ;
Choquette, P ;
Guilbert, E ;
Lefebvre, Y ;
Powell, MG ;
Ross, S ;
Senikas, V ;
Young, R ;
Yuzpe, A .
CONTRACEPTION, 1997, 55 (03) :139-144
[8]   The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors [J].
Archer, DF ;
Mammen, EF ;
Grubb, GS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) :S63-S66
[9]   Guest Editorial -: Alesse®:: Leading the shift to 20 μg [J].
Archer, DF .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) :S37-S38
[10]   Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®) [J].
Archer, DF ;
Maheux, R ;
DelConte, A ;
O'Brien, FB .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) :S39-S44